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positive breast cancers and have occurred predominantly in the
MPG2 and PPG.
doi:10.1016/j.ejcsup.2010.06.026
O-26 DOES THE ADDITIONAL PROGNOSTIC BENEFIT OF
SCREENING IN EARLY BREAST CANCER (EBC) APPLY TO ALL
PATIENTS?
J. Mansell, O. Olusegun, C.R. Wilson, W.J. Angerson, J.C. Doughty.
Western Infirmary, Glasgow, UK
Introduction: Screen detection may confer prognostic benefit
independent of disease stage in EBC leading to suggestions that
mode of presentation should be considered when deciding adju-
vant therapy. We aim to determine if this additional prognostic
benefit is seen in all patients.
Methods: Data from 3 centres in Glasgow of consecutive
women aged between 50 and 65 years with EBC diagnosed
between 1995 and 2001 were examined. Patients were grouped
by mode of presentation into screen detection and symptomatic.
Breast cancer specific survival was the end-point. Multivariate
analysis including interaction between mode of presentation
and pathology was performed with further subgroup analysis if
the interaction was significant.
Results: Women (1534) were included with a median follow-up
of 5.5 years. Mode of presentation was screening in 1007 (65.6%)
women. After adjustment for pathology screen detection had no
significant survival benefit: HR 0.73 (0.50–1.08, p = 0.116). Mode
of presentation had an independently significant interaction with
both nodal status and ER status (p = 0.003 and p = 0.01 respec-
tively). Further analysis demonstrated that screening was an
independent predictor of survival in the 1–3 node positive group
(HR 0.33 (0.15–0.73), p = 0.006); the ER positive group (HR 0.53
(0.31–0.89), p = 0.017) and in the moderate NPI group only (HR
0.54 (0.31–0.94), p = 0.030).
Conclusions: These results provide evidence of a significant
interaction between mode of presentation and pathology. Further
research is needed before incorporating mode of presentation
into decisions regarding adjuvant therapy.
doi:10.1016/j.ejcsup.2010.06.027
O-27 EPITHELIAL PROLIFERATION (Ki67) IS PROGNOSTIC IN
SYMPTOMATIC BUT NOT SCREEN DETECTED BREAST CANCERS
(SDBC)
N.J. Bundred a, W.F. Knox b, A. Cramer c,d, M. Wilson e, R. Prasad a,
J. Morris f. aAcademic Department of Surgery, University Hospital of
South Manchester, Manchester, UK. bAcademic Department of
Pathology, University Hospital of South Manchester, Manchester,
UK. cDepartment of Histopathology, Christie Hospital, Manchester,
UK. dDepartment of Cytogenetics, Christie Hospital, Manchester,
UK. eAcademic Department of Radiology, University Hospital of South
Manchester, Manchester, UK. fAcademic Department of Statistics,
University Hospital of South Manchester, Manchester, UK
Epithelial proliferation has been used to determine therapy in
the St. Gallen guidelines (Ki67 P30% indicates the need for che-
motherapy). UK screen detected breast cancers (SDBC) (aged 50–
65 years) have an overall 97.2% 5 year relative survival compared
to 77.6% for symptomatic cancers.
To determine the value of Ki67 in post-menopausal breast
cancer in women aged 50–65 years, we have studied Ki67 in
1270 women with either symptomatic cancers (n = 412) or SDBC
(n = 858). Mean Ki67 in SDBC was 21.4 (SD 10.3) and 34.2 (SD
16.2) in symptomatic cancers (p = 60.001). For each 10 unit
increase in Ki67, increases in distant relapse occurred (RR 1.43:
95%CI; 1.32–1.55). Twelve per cent of symptomatic and 2% of SDBC
had died within 5 years.
Out of 458 women with Ki67 620, 27 died within 10 years
(93.2% survival) compared to 143 out of 775 with Ki67 P20%
(79% survival) (p = 60.001).
Ki67 was prognostic for symptomatic cancers of distant
relapse (p = 0.01) and mortality (p = 0.01) but was only predic-
tive of recurrence (p = 0.01) and not mortality in SDBC. In
SDBC, Ki67 values in the 2% who died did not differ from
those alive at 5 years and use of cut-off score of Ki67 of
P20% would have potentially selected 35% of women for che-
motherapy and a Ki67 of P30% would have potentially
selected 12% of women.
Epithelial proliferation is prognostic, but not predictive, of
chemotherapy benefit in SDBC.
doi:10.1016/j.ejcsup.2010.06.028
O-28 FACTORS ASSOCIATEDWITH A COMPLETE PATHOLOGICAL
RESPONSE FOLLOWING NEO-ADJUVANT CHEMOTHERAPY FOR
BREAST CANCER
Angharad Pryce, Weehaan Pang, Adele Francis, Daniel Rea.
University Hospital, Birmingham, UK
Background: Chemotherapy for treatment of breast cancer
has been increasingly used in neo-adjuvant setting to facilitate
pre-operative reduction in tumour size to make amenable to
surgery or to facilitate breast-conserving surgery in the place
of mastectomy. A complete pathological response to chemo-
therapy is associated with a greater overall and disease free
survival.
Purpose: This study aimed to identify molecular markers,
disease and treatment factors associated with complete patho-
logical response to neo-adjuvant chemotherapy in breast
cancer.
Methods: Fifty-six patients who received neo-adjuvant chemo-
therapy at our institution between January 2006 and January 2010
with complete histological information and definitive surgery at
the time of data collection were identified. Age, type, grade, cate-
gory of cancer, molecular markers including ER, PR, HER2, imag-
ing size, nodal status, chemotherapy regimen and pathological
response were recorded. Chi squared and Fisher Exact test were
used for statistical analysis.
Results: Eleven patients (19.6%) undergoing neo-adjuvant che-
motherapy had a complete pathological response and 6 patients
10 EJC SUPPLEMENTS 8 (2010) 1–36
(10.7%) had >90% reduction in tumour size. 6 of the 11 with cPR
were HER2 positive, 3 triple negative and 2 luminal type (ER+ve,
PR+ve, HER2–ve).
71.4% of ERBB2 tumours (ER–ve HER2+ve), all with trast-
uzumab included in their chemotherapy regimen, had cPR. This
molecular subtype was significantly more likely to achieve cPR
than luminal subtype (p < 0.05). Oestrogen negative tumours
were more likely to respond then oestrogen positive tumours
(p < 0.05).
Conclusions: This study suggests that Her 2positive, ER–ve high
grade ductal tumours are the most chemosensitive. The results
support the use of trastuzumab in the neo-adjuvant setting. Data
collection is ongoing.
doi:10.1016/j.ejcsup.2010.06.029
O-29 CAN ER/PR AND HER2 RECEPTOR STATUS PREDICT COM-
PLETE PATHOLOGICAL RESPONSE AFTER NEO-ADJUVANT CHE-
MOTHERAPY IN PATIENTS WITH BREAST CANCER?
T. Sircar, R. Athwal, H. Brown, D. Dea, F. Hoar. Birmingham City
Hospital, Birmingham, UK
Aim: The complete pathological response (CPR) rate of the
breast following neo-adjuvant chemotherapy (NAC) in patients
with breast cancer varies from 13% to 29%. The aim of this study
was to establish the incidence of CPR in our unit and investigate if
CPR could be predicted using oestrogen receptor (ER), progester-
one receptor (PR) and human epidermal growth factor receptor
2 (HER2) status.
Method: Patients with breast cancer diagnosed between Janu-
ary 2006 and October 2009 who had NAC followed by surgery were
included in the study.
Results: (See Table 1) Altogether 38 patients had NAC followed
by surgery. Mean clinical size of the tumour was 72 mm. The
commonest chemotherapy regime was Epirubicin-CMF. 8/10
HER2 positive patients received neo-adjuvant trastuzumab. Over-
all 18% (7/38) of patients achieved CPR of the breast and 16% (6/38)
achieved CPR of breast and axilla. The rate of CPR of the breast
was highest in triple negative patients (36%) and ER negative
patients (32%). Post NAC axillary nodes were negative in 45% of
patients (n = 17).
Conclusions: Complete pathological response of the breast was
seen in 18% of patients. ER, PR and HER2 receptor expression
appears to be relevant when predicting CPR, with triple negative
tumours having the highest chance of CPR (36%).
doi:10.1016/j.ejcsup.2010.06.030
O-30 BASAL-LIKE PHENOTYPE IS A PROGNOSTIC MARKER OF
LOCALLY ADVANCED BREAST CANCER BUT NOT A PREDICTIVE
MARKER OF RESPONSE TO NEOADJUVANT ANTHRACYCLINE
CHEMOTHERAPY
M. Shehata, A. Mukherjee, P. Moseley, E. Rakha, I. Ellis, S. Chan.
Nottingham University Hospitals, Nottingham, UK
The basal-like breast cancer is associated with aggressive
behaviour and poor prognosis. In this study we examined the
impact of two different definitions of basal phenotype (BP) on
its prognostic significance in locally advanced primary breast
cancer (LAPC) treated by neoadjuvant anthracycline combination
chemotherapy.
Method: This study included 120 patients diagnosed with LAPC
from 1999 to 2007 at Nottingham University Hospital. IHC was
used for evaluation of a number of markers including ER, PR,
HER2, EGFR, and CK5/6, and CK14. BP was defined in 2 ways as
either any positive expression of CK5/6 and/or CK14 or double
negative expression for ER and HER2 plus positive expression
for CK5/6 and/or EGFR. BP and triple negative (TN) status were
correlated with pCR, PFS and OS.
Result: BP was positive in 46.3% and 24.8% of the cases accord-
ing to the 1st and 2nd definitions. Twenty-nine percent of the
patients were TN. Median follow-up was 62 months. Both defini-
tion did not correlate with pCR to chemotherapy while TN corre-
lated with pCR (p = 0.004). RFS and OS were not significantly
different when the 1st definition of BP was used but were signif-
icant with the 2nd definition (p = 0.016 and <0.001). TN patients
had poor RFS and OS but it was only significant for OS (p = 0.007).
Conclusion: BP in this patient population is an important prog-
nostic but not predictive marker of pCR to anthracycline neoadju-
vant chemotherapy.
The predictive and prognostic value of TN and BP are different,
further studies to clarify the clinical utilities in LAPC are
necessary.
doi:10.1016/j.ejcsup.2010.06.031
Table 1
ER+ ER– HER2+ HER2– ER+HER2+ ER+HER2– ER– PR-HER2+ ER–PR–HER2–(triple–)
Total (n = 38) Total (n = 38) Total (n = 38)
Number and % of patients 19 (50%) 19(50%) 10 (26%) 28 (74%) 5 (13%) 14 (37%) 5 (13%) 14 (37%)
Rate of CPR 5% 32% 10% 21% 0 7% 20% 36%
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